Molecular signatures distinguishing tauopathies
(2024)
Files
ThèseNKNZ_October2023.pdf
Restricted Access - Adobe PDF
- 9.33 MB
Details
- Authors
- Supervisors
- Abstract
- Alzheimer’s disease and primary tauopathies are neurodegenerative disorders involving the aggregation of different isoforms of the tau protein (named either 4R or 3R). Currently, their definite differential diagnosis can only be obtained after brain autopsy by analyzing tau isoforms observed in aggregates. So far, the analysis of tau isoforms in body fluids did not allow distinguishing between Alzheimer and primary tauopathies. First, we discovered that the typical differences in 4R and 3R tau isoforms distinguishing between primary tauopathies was only observed in brain tau aggregates, not in its soluble fraction of the brain. Secondly, we observed that specific biochemical modifications on the soluble tau protein were associated with a preferential aggregation of certain tau isoforms, providing thus potential targets for future biomarker development in body fluids. Finally, we highlighted soluble tau post-translational modifications that could prevent tau from aggregating, opening new research avenues for developing treatments against Alzheimer’s disease and primary tauopathies.
- Affiliations
Citations
Kyalu Ngoie Zola, N. (2024). Molecular signatures distinguishing tauopathies. https://hdl.handle.net/2078.5/29752